FTRE Quote, Financials, Valuation and Earnings

Organon & has a net margin of -86.43% compared to Fortrea Holdings's net margin of 5.75%. Fortrea Holdings's return on equity of -58.22% beat Organon &'s return on equity of 220.72%.

Fortrea Holdings has a consensus price target of $6.66, signalling upside risk potential of 34.53%. On the other hand Organon & has an analysts' consensus of $13.33 which suggests that it could grow by 38.31%. Given that Organon & has higher upside potential than Fortrea Holdings, analysts believe Organon & is more attractive than Fortrea Holdings.

Fortrea Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Organon & has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Fortrea Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Organon & offers a yield of 8.92% to investors and pays a quarterly dividend of $0.02 per share. Fortrea Holdings pays -- of its earnings as a dividend. Organon & pays out 34.38% of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortrea Holdings quarterly revenues are $651.3M, which are smaller than Organon & quarterly revenues of $1.5B. Fortrea Holdings's net income of -$562.9M is lower than Organon &'s net income of $87M. Notably, Fortrea Holdings's price-to-earnings ratio is -- while Organon &'s PE ratio is 3.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings is 0.17x versus 0.40x for Organon &. Usually stocks with elevated PS ratios are considered overvalued.

UroGen Pharma has a net margin of -86.43% compared to Fortrea Holdings's net margin of -216.47%. Fortrea Holdings's return on equity of -58.22% beat UroGen Pharma's return on equity of --.

Fortrea Holdings has a consensus price target of $6.66, signalling upside risk potential of 34.53%. On the other hand UroGen Pharma has an analysts' consensus of $34.38 which suggests that it could grow by 123.07%. Given that UroGen Pharma has higher upside potential than Fortrea Holdings, analysts believe UroGen Pharma is more attractive than Fortrea Holdings.

Fortrea Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison UroGen Pharma has a beta of 1.017, suggesting its more volatile than the S&P 500 by 1.724%.

Fortrea Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UroGen Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortrea Holdings pays -- of its earnings as a dividend. UroGen Pharma pays out -- of its earnings as a dividend.

Fortrea Holdings quarterly revenues are $651.3M, which are larger than UroGen Pharma quarterly revenues of $20.3M. Fortrea Holdings's net income of -$562.9M is lower than UroGen Pharma's net income of -$43.8M. Notably, Fortrea Holdings's price-to-earnings ratio is -- while UroGen Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings is 0.17x versus 7.78x for UroGen Pharma. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of -86.43% compared to Fortrea Holdings's net margin of 12.87%. Fortrea Holdings's return on equity of -58.22% beat West Pharmaceutical Services's return on equity of 17.47%.

Fortrea Holdings has a consensus price target of $6.66, signalling upside risk potential of 34.53%. On the other hand West Pharmaceutical Services has an analysts' consensus of $278.84 which suggests that it could grow by 25.84%. Given that Fortrea Holdings has higher upside potential than West Pharmaceutical Services, analysts believe Fortrea Holdings is more attractive than West Pharmaceutical Services.

Fortrea Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.088, suggesting its more volatile than the S&P 500 by 8.813%.

Fortrea Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.38% to investors and pays a quarterly dividend of $0.21 per share. Fortrea Holdings pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fortrea Holdings quarterly revenues are $651.3M, which are smaller than West Pharmaceutical Services quarterly revenues of $698M. Fortrea Holdings's net income of -$562.9M is lower than West Pharmaceutical Services's net income of $89.8M. Notably, Fortrea Holdings's price-to-earnings ratio is -- while West Pharmaceutical Services's PE ratio is 34.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortrea Holdings is 0.17x versus 5.61x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.